ATOSSA THERAPEUTICS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ATOSSA THERAPEUTICS, INC. (ATOS) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$54.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2023-11-13
- ATOSSA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2022-09-30 was -$54.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month |
|---|---|
| 2022-09-30 | -$54.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |